ACXP实时信号 | 通过Getagraph.com最大化利润

Live Chart Being Loaded With Signals

Commentary (27 Apr 2024 @ 04:00):

Stats
今日成交量	28 594.00
平均成交量	99 434.00
市值	32.62M
EPS	$-0.380 ( 2024-03-18 )
下一个收益日期	( $-0.240 ) 2024-05-10
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-1.800
ATR14	$0.0140 (0.68%)

Insider Trading

Date	Person	Action	Amount	type
2024-02-23	Luci David P	Buy	250 000	Stock Option
2024-02-23	Shawah Robert G.	Buy	145 000	Stock Option
2024-02-23	Deluccia Robert J	Buy	250 000	Stock Option
2024-01-19	Sailer Carl	Buy	19 737	Common Stock
2024-01-19	Sailer Carl	Sell	19 737	Warrants for Common Stock

INSIDER POWER
76.75
Last 61 transactions
Buy: 3 435 791 \| Sell: 229 212

音量相关性

長: 0.26 (neutral)

短: 0.65 (weak)

Signal:(59.834) Neutral

Acurx Pharmaceuticals, 相关性

10 最正相关
SISI	0.968
GLMD	0.965
PEAR	0.963
GMBL	0.962
PPBT	0.951
LAWS	0.948
ACET	0.945
PTE	0.944
NCBS	0.944
CYTO	0.942

10 最负相关
GXII	-0.969
CLBT	-0.961
GASS	-0.958
ISEE	-0.958
RAM	-0.957
MITA	-0.957
NECB	-0.956
IVCB	-0.955
AGGR	-0.955
CSWC	-0.954

你知道吗？

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1，其中-1表示完全负相关（一个变量增加，另一个变量减少），1表示完全正相关（一个变量增加，另一个变量也增加），0表示没有相关性（变量之间没有关系）。

相关性可用于分析任何两个变量之间的关系，而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

Acurx Pharmaceuticals, 相关性 - 货币/商品

-0.20
( neutral )

-0.30
( neutral )

0.00
( neutral )

0.02
( neutral )

0.00
( neutral )

-0.01
( neutral )

Acurx Pharmaceuticals, 财务报表

Annual	2023
营收:	$0
毛利润:	$0 (0.00 %)
EPS:	$-1.150

FY	2023
营收:	$0
毛利润:	$0 (0.00 %)
EPS:	$-1.150

FY	2022
营收:	$0
毛利润:	$0 (0.00 %)
EPS:	$-1.120

FY	2021
营收:	$0.00
毛利润:	$0.00 (0.00 %)
EPS:	$-1.490

Financial Reports:

No articles found.

Acurx Pharmaceuticals,

Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. Its lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that has completed Phase II clinical trial to treat patients with clostridium difficile infections. The company is also developing ACX-375C, a potential oral and parenteral treatment targeting gram-positive bacteria, including methicillin-resistant staphylococcus aureus, vancomycin-resistant enterococcus, and penicillin-resistant streptococcus pneumoniae. Acurx Pharmaceuticals, Inc. was incorporated in 2017 and is headquartered in Staten Island, New York.